Electronic Resource
Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis.
| العنوان: | Recombinant human luteinizing hormone increases endometrial thickness in women undergoing assisted fertility treatments: a systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Mao, R, Hou, X, Feng, X, Wang, R, Fei, X, Zhao, J, Chen, H, Cheng, J |
| بيانات النشر: | Frontiers 2024 |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | INTRODUCTION: The optimal dosage of recombinant human luteinizing hormone (r-hLH) and its impact on endometrial thickness (EMT) when administered alongside recombinant human follicle-stimulating hormone (r-hFSH) during controlled ovarian stimulation (COS) for in vitro fertilization/intracytoplasmic sperm injection and embryo transfer are uncertain, which formed the aims of this systematic review and meta-analysis. METHOD: A search was performed in PubMed, Cochrane Library, Web of Science, EMBASE, CNKI, and Wanfang from its inception to 10 July 2023. Twenty-seven Randomized controlled trials comparing r-hFSH/r-hLH co-treatment with r-hFSH alone during in vitro fertilization/intracytoplasmic sperm injection and embryo transfer (IVF/ICSI-ET) were included. Pooled odds ratios (OR) for dichotomous data and mean differences (MD) for continuous data, with their respective 95% confidence intervals (CI), were generated. Meta-analysis employed fixed-effect or random-effect models based on heterogeneity, using Q-test and I2-index calculations. The main outcomes included EMT on trigger day, clinical pregnancy rate (CPR) and live birth rate (LBR). RESULTS: r-hFSH/r-hLH significantly increased EMT on trigger day (MD = 0.27; 95% CI, 0.11-0.42; I2 = 13%), but reduced oocyte number (MD = -0.60; 95% CI, -1.07 to -0.14; I2 = 72%) and high-quality embryos (MD = -0.76; 95% CI, -1.41 to -0.10; I2 = 94%) than r-hFSH alone, more pronounced with the gonadotrophin-releasing hormone agonist long protocol. A subgroup analysis showed r-hLH at 75 IU/day increased CPR (OR = 1.23; 95% CI, 1.02-1.49; I2 = 16%) and EMT on trigger day (MD = 0.40; 95% CI, 0.19-0.61; I2 = 0%). Participants ≥35 years of age exhibited decreased retrieved oocytes (MD = -1.26; 95% CI, -1.78 to -0.74; I2 = 29%), but an increase in EMT on trigger day (MD = 0.26; 95% CI, 0.11-0.42; I2 = 29%). CONCLUSION: r-hFSH/r-hLH during COS significantly improved EMT compared to r-hFSH alone. An r-hLH dose of 75 IU/day may be considered f |
| مصطلحات الفهرس: | 1115 Pharmacology and Pharmaceutical Sciences, Journal Article |
| URL: | Front Pharmacol 10.3389/fphar.2024.1434625 |
| الاتاحة: | Open access content. Open access content This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
| Other Numbers: | LT1 oai:opus.lib.uts.edu.au:10453/180443 Front Pharmacol, 2024, 15, pp. 1434625 1663-9812 1663-9812 1455950302 |
| المصدر المساهم: | UNIV OF TECH, SYDNEY From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1455950302 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |